Caring Brands, Inc. (NASDAQ:CABR) Short Interest Up 207.7% in June

Caring Brands, Inc. (NASDAQ:CABR) saw a significant increase in short interest during the month of June. As of June 15th, there was short interest totaling 63,992 shares, an increase of 207.7% from the May 31st total of 20,796 shares. Based on an average daily trading volume, of 85,538 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.8% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Caring Brands from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Caring Brands Stock Performance

Shares of CABR opened at $1.24 on Tuesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.66 and a quick ratio of 5.62. The company’s 50-day moving average is $1.12. Caring Brands has a 52 week low of $0.71 and a 52 week high of $5.35. The firm has a market capitalization of $11.27 million and a price-to-earnings ratio of -1.94.

Caring Brands (NASDAQ:CABR) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.27) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Caring Brands stock. Jane Street Group LLC purchased a new position in shares of Caring Brands, Inc. (NASDAQ:CABR) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands at the end of the most recent reporting period.

Caring Brands Company Profile

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.